Table 1.
Patients and transplantation characteristics
| Patients characteristics | N = 46 (%) |
|---|---|
| Age (y) | |
| Median | 60 |
| Range | 18-74 |
| Sex | |
| Male | 25 (54) |
| Female | 21 (46) |
| Race or ethnicity | |
| Caucasian | 27 (59) |
| Hispanic | 12 (26) |
| African American | 5 (11) |
| Asian | 2 (4) |
| HCT-CI | |
| 0 | 17 (37) |
| 1-2 | 19 (41) |
| ≥3 | 10 (22) |
| Disease | |
| AML | 16 (35) |
| MDS | 7 (15) |
| ALL | 16 (35) |
| MF | 1 (2) |
| T-cell NHL | 5 (11) |
| BPDCN | 1 (2) |
| Disease-risk index | |
| Low | 2 (4) |
| Intermediate | 29 (63) |
| High | 14 (30) |
| N/A | 1 (2) |
| Disease status | |
| Complete remission | 35 (76) |
| Active disease | 10 (22) |
| Unknown | 1 (2) |
| CMV status (D/R) | |
| −/− | 13 (28) |
| +/− | 2 (4) |
| −/+ | 9 (20) |
| +/+ | 22 (48) |
| Conditioning regimen | |
| FluCy TBI (NMA) | 16 (35) |
| FluCyBu TBI (RIC) | 5 (11) |
| FluCyBu (MA) | 14 (30) |
| Flu TBI (MA) | 11 (24) |
| CD34+cell dose (106cells per kg) | |
| Median | 6.5 |
| Range | 2.6-10.3 |
AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; BPDCN, blastic plasmacytoid dendritic cell neoplasm; Bu, busulfan; CMV, cytomegalovirus; D/R, donor/recipient; Flu, fludarabine; MA, myeloablative; MDS, myelodysplastic syndrome; MF, myelofibrosis; NHL, non-Hodgkin lymphoma.